Imlunestrant, a next-generation SERD, improves progression-free survival in ER-positive advanced breast cancer patients ...
Pfizer Inc. (NYSE:PFE) and Alliance Foundation Trials, LLC (AFT) announced results from the Phase 3 PATINA trial. The trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback